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Atezolizumab is a monoclonal antibody immune check-
point inhibitor that binds to programmed death ligand 
1 to selectively prevent its interaction with programmed 
cell death-1 (PD-1) and B7.1 (CD80) receptors. We present 
a case of a 61-year-old man with metastatic urothelial car-
cinoma of the right ureter and urinary bladder. After gem-
citabine/cisplatin as the first-line chemotherapy and sur-
gery, the patient received atezolizumab 1200 mg i.v. q3w. 
Following the first atezolizumab administration, he noted 
vitiligo periorally, on his hands, legs, and the scalp. The pa-
tient’s overall survival (OS) of >26 months and continuing 
response to atezolizumab treatment is considerably bet-
ter than median OS in the SAUL study of 8.7 months (IM-
vigor211-like patients’ OS 10.0 months). This case indicates 
that increased efficacy of atezolizumab can be associated 
with cutaneous immune related adverse events, reflecting 
the known Th17 polarization of these diseases and show-
ing that individuals with cutaneous adverse events could 
benefit from PD-1 checkpoint blockade in the therapy of 
metastatic urothelial carcinoma.
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Atezolizumab is a humanized monoclonal antibody that 
prevents the binding of programmed death ligand 1 (PD-
L1) to the programmed cell death-1 (PD-1) and B7.1 (also 
known as CD80) receptor. PD-L1, a transmembrane pro-
tein expressed on tumor cells, upon binding to PD-1 and 
CD80 reduces anti-tumor T-cell activity (1). Atezolizumab is 
prescribed for the therapy of triple negative, metastatic, or 
locally advanced breast cancer, extensive stage small cell 
lung cancer, non-small cell lung cancer, and urothelial car-
cinoma that has progressed during or after a prior plati-
num-based chemotherapy (2-6).
Case RepoRt
A 61-year-old, well developed, well nourished, white male, 
who smoked a pack daily for 45 years but was otherwise 
healthy, was admitted to our department in June 2015 for 
recurrent hematuria, requiring transurethral resection of 
the urinary bladder, which revealed a urothelial papillary 
carcinoma G2. Multi-slice computed tomography (MSCT) 
scan in July 2015 demonstrated bilateral ureterovesical 
junction infiltration by the tumor, with right hydronephro-
sis and multiple pulmonary metastases (Table 1). Due to a 
deteriorating renal function (creatinine 564 µmol/L, blood 
urea nitrogen [BUN] 22.3 mmol/L), in September 2015 a 
right sided “JJ” catheter was placed, which led to an im-
provement in kidney function (creatinine 153 µmol/L, BUN 
9 mmol/L). The patient had Eastern Cooperative Oncology 
Group (ECOG) performance status 0. From October 2015 
to April 2016, six cycles of gemcitabine/cisplatin chemo-
therapy were administered, with a MSCT scan reevaluation 
after three months showing a regression of pulmonary 
metastases and a control MSCT scan after chemotherapy 
showing stable disease.
In June 2016, the patient underwent radical cystecto-
my with pelvic lymphadenectomy, left ureterocutaneous 
anastomosis, and right nephrectomy. Pathohistology re-
taBLe 1. patient care timeline
time event
June 2015 Urothelial papillary carcinoma G2 diagnosed
July 2015 Right hydronephrosis with multiple pulmonary metastases diagnosed
September 2015 Right sided “JJ” catheter placement
October 2015 to April 2016 Six cycles of gemcitabine/cisplatin chemotherapy
June 2016 Radical cystectomy, pelvic lymphadenectomy, left ureterocutaneous anastomosis, and right nephrectomy
June 2016 Pathohistology: urothelial carcinoma of the right ureter G2 pT2 N0 and urothelial carcinoma of the urinary 
bladder G2 pT1 N0
February 2017 Pulmonary disease progression
April 2017 SAUL study enrolment
May 2017 First atezolizumab (Tecentriq®)1200 mg i.v. q3w applied
May 2017 Development of vitiligo periorally, on hands, legs, and the scalp
July 2018 Right temporal region lipoma removal
February 2019 Stereotactic body radiation therapy of 55 Gy for a solitary pulmonary metastasis
April 2019 The 32nd atezolizumab (Tecentriq®) cycle
FiGuRe 1. Vitiligo on patient’s hands.
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vealed two tumors: urothelial carcinoma of the right ureter, 
G2 pT2 N0, and urothelial carcinoma of the urinary blad-
der, G2 pT1 N0, measuring 1 × 2 cm and 11 × 9 cm, respec-
tively (pN = 0/16, R0). In February 2017, pulmonary disease 
progression was noted. In April 2017, he was enrolled into 
the SAUL study and in May 2017 first received atezolizum-
ab (Tecentriq®; Hoffmann-La Roche AG, Basel, Switzerland) 
1200 mg i.v. q3w (7). Over the following 3 months, the two 
metastatic pulmonary lesions were considerably reduced 
in size, from 21 and 14 mm to 7 and 4 mm, respectively. Fol-
lowing the first atezolizumab administration in May 2017, 
the patient noted vitiligo periorally, on his hands (Figure 
1), legs (Figure 2), and the scalp. He also experienced G2 
fatigue and transient hypothyroidism. In July 2018, he not-
ed a soft-tissue growth in the right temporal region, which 
was pathologically confirmed to be a lipoma.
Control MSCT scan in February 2019 showed that a solitary 
pulmonary metastasis grew from 7 to 15.25 mm, which is 
why stereotactic body radiation therapy of 55 Gy was ap-
plied. In April 2019, the 32nd atezolizumab cycle was ad-
ministered. Now, 45 months after the diagnosis, the pa-
tient is 65 years old, with ECOG = 0. He responded to the 
first-line treatment with gemcitabine and cisplatin, which 
lasted for 16 months. His response to second-line atezoli-
zumab therapy, with concomitant development of vitiligo 
as an immune related adverse event (irAE), still continues 
after 26 months of treatment.
DisCussioN
A few smaller clinical studies suggested that dermatologi-
cal immune related adverse events following the admin-
istration of checkpoint inhibitors can be associated with 
treatment efficacy (8). Khan et al demonstrated that pa-
tients who experienced low-grade dermatological irAEs 
had longer OS in IMvigor211 (P = 0.024; hazard ratio [HR] 
0.66; 95% confidence interval [CI] 0.45-0.95) and IMvig-
or210 (P = 0.0023; HR 0.53; 95% CI 0.35-0.80) trials (9). In 
their analysis, polygenic risk for psoriasis was associated 
with an increased odds of skin irAEs (P = 0.002; OR 1.79; 
95% CI 1.24-2.40), while high polygenic risks for vitiligo (P 
= 0.0016; HR 0.58; 95% CI 0.41-0.81) and psoriasis (P = 5.5 
× 10−5; HR 0.50; 95% CI 0.36-0.70), as well as low for atopic 
dermatitis (P = 0.0008; HR 0.57; 95% CI 0.41-0.79) were as-
sociated with longer OS under anti-PD-L1 atezolizumab 
monotherapy in compari son with chemotherapy (9).
Our patient’s OS of >23 months on atezolizumab in the 
second-line therapy is considerably higher than the me-
dian OS in the SAUL study of 8.7 months (IMvigor211-like 
patients OS 10.0 months) and, in our opinion, it highlights 
that concomitant skin autoimmunity can be associated 
with increased efficacy of atezolizumab in the treatment of 
metastatic urothelial carcinoma (7,10).
In conclusion, a positive association between overall sur-
vival and skin irAEs (vitiligo and psoriasis) reflects the 
known Th17 polarization of these diseases, indicating that 
individuals with high Th17 polarization benefit from PD-1 
checkpoint blockade in the therapy of metastatic urotheli-
al carcinoma. Genetic background and tumor factors likely 
interact and affect survival benefit associated with check-
point blockade as compared with chemotherapy. Median 
OS in the second-line with classical chemotherapy for met-
astatic urothelial carcinoma is 6-9 months (10). Our patient 
remains asymptomatic with ECOG = 0 and an ongoing re-
sponse to atezolizumab therapy for more than 26 months.
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